The antipsychotic drug lurasidone inhibits coronaviruses by affecting multiple targets
Sara Baroni, Tea Carletti, Manuela Donalisio, Irene Arduino, Irene Cazzaniga, Toni Giorgino, Francesca Esposito, Alessia Porta, Luisa Diomede, Ada De Luigi, Marco Gobbi, David Lembo, Alessandro Marcello, Enzo Tramontano, Mario Milani, Eloise Mastrangelo · 2024
Read The antipsychotic drug lurasidone inhibits coronaviruses by affecting multiple targets by Sara Baroni, Tea Carletti, Manuela Donalisio, Irene Arduino, Irene Cazzaniga, Toni Giorgino, Francesca Esposito, Alessia Porta, Luisa Diomede, Ada De Luigi, Marco Gobbi, David Lembo, Alessandro Marcello, Enzo Tramontano, Mario Milani, Eloise Mastrangelo (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11625747.txt.
Description
A schizophrenia drug that also fights coronaviruses gets its mechanism pinned down in a 2024 study by Sara Baroni and co-authors. The drug, lurasidone, had already shown activity against both SARS-CoV-2 and a common-cold coronavirus in earlier work.
Lab tests now point to two targets. The drug blocks a viral cutting enzyme shared by both viruses, which the virus needs to copy itself. Against SARS-CoV-2 it also strikes the spike protein, hindering entry into cells. Infected cells treated with the drug carried far less virus. The authors pitch the borrowed medicine as a dual-action candidate worth developing further, since future coronaviruses would likely share the same weak points.
Catalog record
| CREATOR | Sara Baroni, Tea Carletti, Manuela Donalisio, Irene Arduino, Irene Cazzaniga, Toni Giorgino, Francesca Esposito, Alessia Porta, Luisa Diomede, Ada De Luigi, Marco Gobbi, David Lembo, Alessandro Marcello, Enzo Tramontano, Mario Milani, Eloise Mastrangelo |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |